← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,201	+21	+2%	$14.9B
2	2 Charles River Laboratories CRL $14.4B	611	-10	-2%	$10.7B
3	3 DELISTED CATALENT, INC. CTLT	441	-85	-16%	$8.72B
4	4 CRISPR Therapeutics CRSP $4.86B	417	+36	+9%	$3.07B
5	5 Sarepta Therapeutics SRPT $1.78B	405	-21	-5%	$9.38B
6	6 Intellia Therapeutics NTLA $1.6B	290	-1	-0.3%	$3.19B
7	ISEE 7 DELISTED IVERIC bio, Inc. Common Stock ISEE	255	+32	+14%	$5.33B
8	8 Ultragenyx Pharmaceutical RARE $1.47B	242	+13	+6%	$3.21B
9	9 PTC Therapeutics PTCT $4.98B	205	+2	+1%	$3.3B
10	10 Vericel Corp VCEL $2.06B	200	+1	+0.5%	$1.88B
11	11 BridgeBio Pharma BBIO $12.7B	196	-17	-8%	$2.58B
12	12 Legend Biotech LEGN $3.7B	194	+34	+21%	$5.81B
13	13 Fate Therapeutics FATE $232M	188	+7	+4%	$520M
14	14 Krystal Biotech KRYS $9.79B	183	+23	+14%	$2.71B
15	15 uniQure QURE $1.45B	177	+5	+3%	$413M
16	16 DELISTED bluebird bio BLUE	175	-2	-1%	$309M
17	17 Allogene Therapeutics ALLO $449M	171	-5	-3%	$663M
18	18 Regenxbio RGNX $454M	166	-8	-5%	$742M
19	19 Rocket Pharmaceuticals RCKT $243M	164	+1	+0.6%	$1.52B
20	20 DELISTED BioLife Solutions BLFS	156	-13	-8%	$897M
21	21 DELISTED SANGAMO THERAPEUTICS INC SGMO	152	-27	-15%	$137M
22	22 DELISTED 2seventy bio TSVT	149	+2	+1%	$505M
23	23 DELISTED Arcellx ACLX	138	+21	+18%	$1.52B
24	24 Precigen PGEN $2.64B	138	-19	-12%	$66M
25	25 Sana Biotechnology SANA $698M	123	+3	+3%	$804M